{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:14:12Z","timestamp":1791486852201,"version":"4.3.4"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100013238","name":"Faculty of Medicine Siriraj Hospital, Mahidol University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013238","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004156","name":"Mahidol University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004396","name":"Thailand Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004396","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.intimp.2020.107069","type":"journal-article","created":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T22:52:51Z","timestamp":1606171971000},"page":"107069","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"PB","title":["Anti-tumour effect of the fourth-generation chimeric antigen receptor T cells targeting CD133 against cholangiocarcinoma cells"],"prefix":"10.1016","volume":"89","author":[{"given":"Thanich","family":"Sangsuwannukul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamonlapat","family":"Supimon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jatuporn","family":"Sujjitjoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nattaporn","family":"Phanthaphol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thaweesak","family":"Chieochansin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naravat","family":"Poungvarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sopit","family":"Wongkham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mutita","family":"Junking","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pa-thai","family":"Yenchitsomanus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.intimp.2020.107069_b0005","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1634\/theoncologist.2015-0446","article-title":"Forty\u2010year trends in cholangiocarcinoma incidence in the U.S.: intrahepatic disease on the rise","volume":"21","author":"Saha","year":"2016","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.intimp.2020.107069_b0010","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jhep.2019.03.013","article-title":"Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma","volume":"71","author":"Bertuccio","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.intimp.2020.107069_b0015","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2147\/IJGM.S186854","article-title":"Cholangiocarcinoma: a guide for the nonspecialist","volume":"12","author":"Alsaleh","year":"2018","journal-title":"Int. J. Gen. Med."},{"issue":"2","key":"10.1016\/j.intimp.2020.107069_b0020","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.suc.2018.12.004","article-title":"Cholangiocarcinoma","volume":"99","author":"Khan","year":"2019","journal-title":"Surg. Clin. North Am."},{"issue":"6","key":"10.1016\/j.intimp.2020.107069_b0025","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.jceh.2019.08.001","article-title":"Ablative therapy for unresectable intrahepatic cholangiocarcinoma: a systematic review and meta-analysis","volume":"9","author":"Yousaf","year":"2019","journal-title":"J. Clin. Exp. Hepatol."},{"issue":"2","key":"10.1016\/j.intimp.2020.107069_b0030","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/biot.200500044","article-title":"Cancer immunotherapy","volume":"1","author":"Schuster","year":"2006","journal-title":"Biotechnol. J."},{"issue":"4","key":"10.1016\/j.intimp.2020.107069_b0035","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.3892\/ol.2017.6784","article-title":"HLA-mediated tumor escape mechanisms that may impair immunotherapy clinical outcomes via T-cell activation","volume":"14","author":"Rodr\u00edguez","year":"2017","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.intimp.2020.107069_b0040","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.imlet.2017.08.018","article-title":"Current strategies to improve the safety of chimeric antigen receptor (CAR) modified T cells","volume":"190","author":"Yang","year":"2017","journal-title":"Immunol. Lett."},{"issue":"5","key":"10.1016\/j.intimp.2020.107069_b0045","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl. J. Med."},{"issue":"1","key":"10.1016\/j.intimp.2020.107069_b0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yexcr.2018.05.009","article-title":"Antigenic targets of CAR T Cell Therapy. A retrospective view on clinical trials","volume":"369","author":"Arabi","year":"2018","journal-title":"Exp. Cell Res."},{"issue":"4","key":"10.1016\/j.intimp.2020.107069_b0055","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.hbpd.2018.05.005","article-title":"Chimeric antigen receptor-engineered T-cell therapy for liver cancer","volume":"17","author":"Chen","year":"2018","journal-title":"Hepatobiliary Pancreatic Diseases Int."},{"issue":"7","key":"10.1016\/j.intimp.2020.107069_b0060","doi-asserted-by":"crossref","first-page":"107411","DOI":"10.1016\/j.biotechadv.2019.06.010","article-title":"CAR-T immunotherapies: Biotechnological strategies to improve safety, efficacy and clinical outcome through CAR engineering","volume":"37","author":"Panagopoulou","year":"2019","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.intimp.2020.107069_b0065","doi-asserted-by":"crossref","first-page":"S164","DOI":"10.1016\/S1525-0016(16)34024-2","article-title":"First-in-patient proof of safety and efficacy of a 4th generation chimeric antigen receptor-modified T cells for the treatment of relapsed or refractory CD30 positive lymphomas","volume":"23","author":"Ying","year":"2015","journal-title":"Mol Ther"},{"issue":"Suppl. 15","key":"10.1016\/j.intimp.2020.107069_b0070","article-title":"Novel GD2-specific chimeric antigen receptor-modified T cells targeting osteosarcoma. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR","volume":"75","author":"Chulanetra","year":"2015","journal-title":"Cancer Res"},{"issue":"23","key":"10.1016\/j.intimp.2020.107069_b0075","doi-asserted-by":"crossref","first-page":"3774","DOI":"10.1182\/blood.V126.23.3774.3774","article-title":"Chimeric antigen receptor 4SCAR19-modified T cells in acute lymphoid leukemia: a Phase II multi-center clinical trial in China","volume":"126","author":"Dong","year":"2015","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.intimp.2020.107069_b0080","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1182\/blood.V128.22.587.587","article-title":"Safety and efficacy evaluation of 4SCAR19 chimeric antigen receptor-modified T cells targeting B cell acute lymphoblastic leukemia - three-year follow-up of a multicenter Phase I\/II study","volume":"128","author":"Chang","year":"2016","journal-title":"Blood"},{"issue":"Suppl. 3","key":"10.1016\/j.intimp.2020.107069_b0085","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1200\/jco.2014.32.3_suppl.230","article-title":"Variability in immune infiltrates and HLA expression in cholangiocarcinoma","volume":"32","author":"Sabbatino","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.intimp.2020.107069_b0090","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.7314\/APJCP.2015.16.4.1307","article-title":"Current insights on cholangiocarcinoma research: a brief review","volume":"16","author":"Mathema","year":"2015","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"3","key":"10.1016\/j.intimp.2020.107069_b0095","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1080\/1061186X.2018.1479756","article-title":"CD133: beyond a cancer stem cell biomarker","volume":"27","author":"Barzegar Behrooz","year":"2019","journal-title":"J. Drug Target."},{"issue":"Pt 2","key":"10.1016\/j.intimp.2020.107069_b0100","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.semcancer.2018.05.001","article-title":"Cancer stem cells: regulation programs, immunological properties and immunotherapy","volume":"52","author":"Zhang","year":"2018","journal-title":"Semin. Cancer Biol."},{"issue":"17","key":"10.1016\/j.intimp.2020.107069_b0105","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.3390\/ijms20174154","article-title":"Role of cancer stem cells in cholangiocarcinoma and therapeutic implications","volume":"20","author":"Wu","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2020.107069_b0110","first-page":"42","article-title":"New insights into cholangiocarcinoma: multiple stems and related cell lineages of origin","volume":"31","author":"Bragazzi","year":"2018","journal-title":"Ann. Gastroenterol."},{"issue":"3","key":"10.1016\/j.intimp.2020.107069_b0115","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3390\/cancers11030310","article-title":"Recent advances in cancer stem cell-targeted immunotherapy","volume":"11","author":"Badrinath","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.intimp.2020.107069_b0120","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1007\/s13238-017-0394-6","article-title":"Targeting cancer stem cells by using chimeric antigen receptor-modified T cells: a potential and curable approach for cancer treatment","volume":"9","author":"Guo","year":"2018","journal-title":"Protein Cell"},{"issue":"6","key":"10.1016\/j.intimp.2020.107069_b0125","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3390\/toxins8060165","article-title":"CD133, selectively targeting the root of cancer","volume":"8","author":"Schmohl","year":"2016","journal-title":"Toxins (Basel)"},{"key":"10.1016\/j.intimp.2020.107069_b0130","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.pharmthera.2018.02.001","article-title":"Targeting cancer stem cells in the clinic: current status and perspectives","volume":"187","author":"Annett","year":"2018","journal-title":"Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.intimp.2020.107069_b0135","doi-asserted-by":"crossref","first-page":"243","DOI":"10.5732\/cjc.009.10587","article-title":"Research progression of CD133 as a marker of cancer stem cells","volume":"29","author":"Zhang","year":"2010","journal-title":"Chin. J. Cancer"},{"key":"10.1016\/j.intimp.2020.107069_b0140","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.lfs.2017.07.008","article-title":"Potential mechanisms of CD133 in cancer stem cells","volume":"184","author":"Jang","year":"2017","journal-title":"Life Sci."},{"issue":"9","key":"10.1016\/j.intimp.2020.107069_b0145","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.3748\/wjg.v17.i9.1192","article-title":"Strong expression of CD133 is associated with increased cholangiocarcinoma progression","volume":"17","author":"Leelawat","year":"2011","journal-title":"World J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.intimp.2020.107069_b0150","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-018-1423-9","article-title":"CD133 expression in cancer cells predicts poor prognosis of non-mucin producing intrahepatic cholangiocarcinoma","volume":"16","author":"Cai","year":"2018","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/j.intimp.2020.107069_b0155","doi-asserted-by":"crossref","first-page":"171","DOI":"10.18632\/oncotarget.2767","article-title":"Patient-derived glioblastoma stem cells are killed by CD133-specific CAR T cells but induce the T cell aging marker CD57","volume":"6","author":"Zhu","year":"2015","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.intimp.2020.107069_b0160","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-016-0378-7","article-title":"Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma","volume":"10","author":"Feng","year":"2017","journal-title":"J. Hematol. Oncol."},{"issue":"7","key":"10.1016\/j.intimp.2020.107069_b0165","doi-asserted-by":"crossref","first-page":"e1440169","DOI":"10.1080\/2162402X.2018.1440169","article-title":"CD133-directed CAR T cells for advanced metastasis malignancies: a phase I trial","volume":"7","author":"Wang","year":"2018","journal-title":"OncoImmunology"},{"issue":"4","key":"10.1016\/j.intimp.2020.107069_b0170","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1089\/hum.2017.234","article-title":"Nucleofection with plasmid DNA for CRISPR\/Cas9-mediated inactivation of programmed cell death protein 1 in CD133-specific CAR T Cells","volume":"30","author":"Hu","year":"2019","journal-title":"Hum. Gene Ther."},{"issue":"22","key":"10.1016\/j.intimp.2020.107069_b0175","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.3748\/wjg.v11.i22.3392","article-title":"Establishment and characterization of an opisthorchiasis-associated cholangiocarcinoma cell line (KKU-100)","volume":"11","author":"Sripa","year":"2005","journal-title":"World J. Gastroenterol."},{"issue":"3","key":"10.1016\/j.intimp.2020.107069_b0180","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s13577-020-00334-w","article-title":"Functional and genetic characterization of three cell lines derived from a single tumor of an Opisthorchis viverrini-associated cholangiocarcinoma patient","volume":"33","author":"Sripa","year":"2020","journal-title":"Hum. Cell"},{"issue":"3","key":"10.1016\/j.intimp.2020.107069_b0185","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/01.TP.0000110292.73873.25","article-title":"Establishment of a highly differentiated immortalized human cholangiocyte cell line with SV40T and hTERT","volume":"77","author":"Maruyama","year":"2004","journal-title":"Transplantation"},{"issue":"10","key":"10.1016\/j.intimp.2020.107069_b0190","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1007\/s00262-018-2212-2","article-title":"Cytotoxic activity of effector T cells against cholangiocarcinoma is enhanced by self-differentiated monocyte-derived dendritic cells","volume":"67","author":"Panya","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"issue":"10","key":"10.1016\/j.intimp.2020.107069_b0195","doi-asserted-by":"crossref","DOI":"10.1177\/1010428317733367","article-title":"Enhanced cytotoxic activity of effector T-cells against cholangiocarcinoma by dendritic cells pulsed with pooled mRNA","volume":"39","author":"Junking","year":"2017","journal-title":"Tumour Biol."},{"key":"10.1016\/j.intimp.2020.107069_b0200","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/j.freeradbiomed.2013.07.034","article-title":"Inflammation-related DNA damage and expression of CD133 and Oct3\/4 in cholangiocarcinoma patients with poor prognosis","volume":"65","author":"Thanan","year":"2013","journal-title":"Free Radic Biol. Med."},{"issue":"6","key":"10.1016\/j.intimp.2020.107069_b0205","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1016\/j.ajpath.2015.02.010","article-title":"Profiles of cancer stem cell subpopulations in cholangiocarcinomas","volume":"185","author":"Cardinale","year":"2015","journal-title":"Am. J. Pathol."},{"issue":"1","key":"10.1016\/j.intimp.2020.107069_b0210","doi-asserted-by":"crossref","first-page":"13","DOI":"10.5009\/gnl15568","article-title":"Cholangiocarcinoma: current knowledge and new developments","volume":"11","author":"Blechacz","year":"2017","journal-title":"Gut and Liver"},{"issue":"2","key":"10.1016\/j.intimp.2020.107069_b0215","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.tmrv.2019.01.005","article-title":"Risks and benefits of chimeric antigen receptor T-cell (CAR-T) therapy in cancer: a systematic review and meta-analysis","volume":"33","author":"Grigor","year":"2019","journal-title":"Transfus. Med. Rev."},{"issue":"10","key":"10.1016\/j.intimp.2020.107069_b0220","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jcyt.2020.04.088","article-title":"Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: a phase I clinical trial","volume":"22","author":"Liu","year":"2020","journal-title":"Cytotherapy"},{"key":"10.1016\/j.intimp.2020.107069_b0225","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.coi.2017.02.001","article-title":"Stimulating CD27 to quantitatively and qualitatively shape adaptive immunity to cancer","volume":"45","author":"Bullock","year":"2017","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.intimp.2020.107069_b0230","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.copbio.2018.01.025","article-title":"A guide to manufacturing CAR T cell therapies","volume":"53","author":"Vormittag","year":"2018","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.intimp.2020.107069_b0235","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.omtm.2018.11.010","article-title":"Development of a novel anti-CD19 chimeric antigen receptor: a paradigm for an affordable CAR T cell production at academic institutions","volume":"12","author":"Castella","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.intimp.2020.107069_b0240","doi-asserted-by":"crossref","first-page":"101307","DOI":"10.1016\/j.smim.2019.101307","article-title":"Common gamma chain cytokines and CD8 T cells in cancer","volume":"42","author":"Shourian","year":"2019","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.intimp.2020.107069_b0245","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.3389\/fimmu.2018.02692","article-title":"Defining Memory CD8 T Cell","volume":"9","author":"Martin","year":"2018","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2020.107069_b0250","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.smim.2016.02.001","article-title":"Role of memory T cell subsets for adoptive immunotherapy","volume":"28","author":"Busch","year":"2016","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.intimp.2020.107069_b0255","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1023\/A:1023668705040","article-title":"Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis","volume":"8","author":"Chawla-Sarkar","year":"2003","journal-title":"Apoptosis"},{"key":"10.1016\/j.intimp.2020.107069_b0260","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.cyto.2016.08.003","article-title":"TNF activity and T cells","volume":"101","author":"Mehta","year":"2018","journal-title":"Cytokine"},{"key":"10.1016\/j.intimp.2020.107069_b0265","first-page":"3833","article-title":"TNF-\u03b1 is critical for antitumor but not antiviral T cell immunity in mice","volume":"117","author":"Calzascia","year":"2007","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.intimp.2020.107069_b0270","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.3389\/fimmu.2019.01149","article-title":"CAR T cells targeting the tumor MUC1 glycoprotein reduce triple-negative breast cancer growth","volume":"10","author":"Zhou","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2020.107069_b0275","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1182\/blood-2017-08-802926","article-title":"Antitumor activity of CAR-T cells targeting the intracellular oncoprotein WT1 can be enhanced by vaccination","volume":"132","author":"Akahori","year":"2018","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.intimp.2020.107069_b0280","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.immuni.2016.05.014","article-title":"Engineered CAR T cells targeting the cancer-associated Tn-Glycoform of the membrane mucin MUC1 control adenocarcinoma","volume":"44","author":"Posey","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2020.107069_b0285","doi-asserted-by":"crossref","first-page":"16011","DOI":"10.1038\/mto.2016.11","article-title":"Toxicity and management in CAR T-cell therapy","volume":"3","author":"Bonifant","year":"2016","journal-title":"Mol. Ther. Oncolytics"},{"issue":"11","key":"10.1016\/j.intimp.2020.107069_b0290","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.exphem.2016.07.011","article-title":"Improving the safety of T-Cell therapies using an inducible caspase-9 gene","volume":"44","author":"Zhou","year":"2016","journal-title":"Exp. Hematol."},{"issue":"2","key":"10.1016\/j.intimp.2020.107069_b0295","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.hbpd.2018.11.001","article-title":"The effect of adjuvant chemotherapy in resectable cholangiocarcinoma: a meta-analysis and systematic review","volume":"18","author":"Wang","year":"2019","journal-title":"Hepatobiliary Pancreatic Diseases Int."},{"issue":"4","key":"10.1016\/j.intimp.2020.107069_b0300","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.jhep.2019.05.026","article-title":"Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex vivo targeting immune checkpoint molecules","volume":"71","author":"Zhou","year":"2019","journal-title":"J. Hepatol."},{"issue":"9","key":"10.1016\/j.intimp.2020.107069_b0305","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/s41587-019-0192-1","article-title":"CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity","volume":"37","author":"Choi","year":"2019","journal-title":"Nat. Biotechnol."},{"issue":"3","key":"10.1016\/j.intimp.2020.107069_b0310","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.it.2019.01.008","article-title":"T cell-redirecting strategies to \u2018STAb\u2019 tumors: beyond CARs and bispecific antibodies","volume":"40","author":"Blanco","year":"2019","journal-title":"Trends Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2020.107069_b0315","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.cell.2018.05.013","article-title":"Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia","volume":"173","author":"Kim","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2020.107069_b0320","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.coi.2018.03.002","article-title":"Driving CARs on the uneven road of antigen heterogeneity in solid tumors","volume":"51","author":"Chen","year":"2018","journal-title":"Curr. Opin. Immunol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576920326345?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576920326345?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:20:06Z","timestamp":1761585606000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576920326345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":64,"alternative-id":["S1567576920326345"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2020.107069","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-tumour effect of the fourth-generation chimeric antigen receptor T cells targeting CD133 against cholangiocarcinoma cells","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2020.107069","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107069"}}